GSK Makes Largest Acquisition in 8 Years to Boost Cancer Portfolio

Why a U.K. pharma giant is paying a 40% premium to pivot back to oncology

GSK announced a major acquisition, marking its largest purchase in eight years. The acquisition is intended to strengthen the company's cancer drug portfolio. The company had previously scaled back its cancer business efforts. This move represents a strategic reversal of GSK's earlier decision to wind down its cancer operations.